Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1955 1
1956 6
1957 7
1959 1
1960 2
1961 3
1962 1
1963 2
1964 1
1971 1
1972 2
1975 1
1976 3
1977 1
1978 1
1980 2
1981 2
1982 1
1983 3
1984 2
1985 3
1986 1
1987 2
1988 3
1990 2
1991 2
1992 10
1993 6
1994 9
1995 20
1996 25
1997 22
1998 32
1999 17
2000 22
2001 26
2002 15
2003 8
2004 8
2005 11
2006 17
2007 9
2008 12
2009 11
2010 13
2011 13
2012 15
2013 14
2014 18
2015 19
2016 31
2017 15
2018 23
2019 19
2020 14
2021 24
2022 27
2023 46
2024 48
2025 37
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

669 results

Results by year

Filters applied: . Clear all
Page 1
A systematic literature review of clinical trials and therapeutic applications of ibogaine.
Köck P, Froelich K, Walter M, Lang U, Dürsteler KM. Köck P, et al. J Subst Abuse Treat. 2022 Jul;138:108717. doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30. J Subst Abuse Treat. 2022. PMID: 35012793 Free article.
BACKGROUND: Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). ...The published data suggest that ibogaine is an effecti …
BACKGROUND: Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly …
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
Noller GE, Frampton CM, Yazar-Klosinski B. Noller GE, et al. Am J Drug Alcohol Abuse. 2018;44(1):37-46. doi: 10.1080/00952990.2017.1310218. Epub 2017 Apr 12. Am J Drug Alcohol Abuse. 2018. PMID: 28402682 Free article.
The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. ...Ibogaine's legal availability in New Zealand may offer improved outcomes where legislation supports treatment providers to work closely …
The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. ...Ibogain
Magnesium-ibogaine therapy in veterans with traumatic brain injuries.
Cherian KN, Keynan JN, Anker L, Faerman A, Brown RE, Shamma A, Keynan O, Coetzee JP, Batail JM, Phillips A, Bassano NJ, Sahlem GL, Inzunza J, Millar T, Dickinson J, Rolle CE, Keller J, Adamson M, Kratter IH, Williams NR. Cherian KN, et al. Nat Med. 2024 Feb;30(2):373-381. doi: 10.1038/s41591-023-02705-w. Epub 2024 Jan 5. Nat Med. 2024. PMID: 38182784 Free PMC article.
Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium-Ibogaine: the Stanford Traumatic Injury to the CN
Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern.
Ibogaine: a review.
Alper KR. Alper KR. Alkaloids Chem Biol. 2001;56:1-38. doi: 10.1016/s0099-9598(01)56005-8. Alkaloids Chem Biol. 2001. PMID: 11705103 Review. No abstract available.
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.
Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Corkery JM, Canessa C, Martinotti G, Di Giannantonio M. Mosca A, et al. Curr Neuropharmacol. 2023;21(11):2178-2194. doi: 10.2174/1570159X21666221017085612. Curr Neuropharmacol. 2023. PMID: 36263479 Free PMC article.
BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. ...The main outcomes were related to the anti-addictive effect of ibogaine and its cardiac toxicity. A meta-analysis …
BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apo …
How toxic is ibogaine?
Litjens RP, Brunt TM. Litjens RP, et al. Clin Toxicol (Phila). 2016;54(4):297-302. doi: 10.3109/15563650.2016.1138226. Epub 2016 Jan 25. Clin Toxicol (Phila). 2016. PMID: 26807959 Review.
It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. OBJECTIVES: To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. …
It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause fo …
A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE. Cameron LP, et al. Nature. 2021 Jan;589(7842):474-479. doi: 10.1038/s41586-020-3008-z. Epub 2020 Dec 9. Nature. 2021. PMID: 33299186 Free PMC article.
The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals(1). Unlike most medications for the treatment of substance use disorders, anecdotal reports suggest that ibogaine has the potential to treat addiction to various substances, i …
The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals(1). Unlike most medications for the treatm …
Ibogaine in the treatment of substance dependence.
Brown TK. Brown TK. Curr Drug Abuse Rev. 2013 Mar;6(1):3-16. doi: 10.2174/15672050113109990001. Curr Drug Abuse Rev. 2013. PMID: 23627782 Review.
Largely because of ibogaine's status as a Schedule I substance in the U.S., the development of ibogaine's use in the treatment of drug addiction took place outside conventional clinical and medical settings. ...This article outlines major findings from …
Largely because of ibogaine's status as a Schedule I substance in the U.S., the development of ibogaine's use in …
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
Knuijver T, Ter Heine R, Schellekens AFA, Heydari P, Lucas L, Westra S, Belgers M, van Oosteren T, Verkes RJ, Kramers C. Knuijver T, et al. J Psychopharmacol. 2024 May;38(5):481-488. doi: 10.1177/02698811241237873. Epub 2024 Mar 22. J Psychopharmacol. 2024. PMID: 38519421 Free PMC article.
We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. METHODS: The study was performed in 14 subjects with OUD. They received a single dose of 10mg/kg ibogaine hydrochloride. ...CONCLUSIONS: The clearance of i
We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. METHODS: The study was pe …
Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Corkery JM. Corkery JM. Prog Brain Res. 2018;242:217-257. doi: 10.1016/bs.pbr.2018.08.005. Epub 2018 Oct 12. Prog Brain Res. 2018. PMID: 30471681 Review.
Ibogaine is an indole alkaloid found in the root bark of the Iboga shrub native to west Africa possessing hallucinogenic properties. ...Looking forward, there is a need to develop better opiate detoxification treatment against a background of increasing opioid-related fata
Ibogaine is an indole alkaloid found in the root bark of the Iboga shrub native to west Africa possessing hallucinogenic properties.
669 results